New hope for hard-to-treat prostate cancer: triple-drug combo enters human trials
NCT ID NCT07226986
First seen Nov 12, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests a new drug (AMO959) combined with a targeted radiation therapy (177Lu-PSMA-617) and a standard hormone therapy in men whose prostate cancer has spread and is no longer controlled by hormone treatment alone. About 123 adults with PSMA-positive metastatic castration resistant prostate cancer will participate. The goal is to find a safe dose and see if the combination can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMalvern, Victoria, 3144, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGMurdoch, Western Australia, 6150, Australia
-
Novartis Investigative Site
RECRUITINGClermont-Ferrand, 63011, France
-
Novartis Investigative Site
RECRUITINGNantes, 44093, France
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
RECRUITINGGranada, Andalusia, 18014, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28041, Spain
-
Rio Grande Urology
RECRUITINGEl Paso, Texas, 79912, United States
Contact
Contact Email: •••••@•••••
-
Utah Intermountain Medical Center
RECRUITINGMurray, Utah, 84107, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.